HDGF2 Human

Hepatoma-Derived Growth Factor (HDGF) was initially identified as a novel growth factor for hepatoma cells. HDGF is a heparin-binding protein that plays a significant role in cell growth, angiogenesis, and anti-apoptotic processes. The discovery of HDGF led to the identification of several HDGF-related proteins, including Hepatoma-Derived Growth Factor-2 (HDGF-2), which are considered members of a new gene family .

HDGF-2, like its related proteins, is involved in various cellular processes. It is a nuclear-targeted protein that stimulates the proliferation of vascular smooth muscle cells and other cell types. HDGF-2 is highly expressed in tumor cells, where it promotes cell growth and survival. The protein is also involved in organ development and tissue repair, highlighting its importance in both normal physiology and disease states .

HDGF-2 has been found to be highly expressed in various types of cancer, including hepatocellular carcinoma (HCC). Studies have shown that HDGF-2 expression is significantly higher in cancerous tissues compared to adjacent non-cancerous tissues. This elevated expression is associated with poor clinical outcomes, suggesting that HDGF-2 contributes to the development and progression of malignant diseases .

Recombinant HDGF-2 is produced using recombinant DNA technology, which involves inserting the gene encoding HDGF-2 into a suitable expression system, such as E. coli. The recombinant protein is then purified using conventional chromatography techniques. Recombinant HDGF-2 is used in research to study its biological functions and potential therapeutic applications .

Recombinant HDGF-2 is a valuable tool in cancer research. It is used to investigate the molecular mechanisms underlying its role in tumor growth and progression. Additionally, HDGF-2 is studied for its potential as a therapeutic target. By understanding how HDGF-2 contributes to cancer, researchers aim to develop targeted therapies that can inhibit its activity and reduce tumor growth .